Dr. Hartshorn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
830 Harrison Ave
Moakley, 3rd Floor
Boston, MA 02118Phone+1 617-638-6248Fax+1 617-638-5756
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1983 - 1986
Boston University Medical CenterResidency, Internal Medicine, 1980 - 1983
Albert Einstein College of MedicineClass of 1980
Certifications & Licensure
MA State Medical License 1982 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Boston Magazine Castle Connolly, 2010-2013
Clinical Trials
- Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
- Study of Panitumumab in the Treatment of Carcinoid Syndrome Start of enrollment: 2013 Jul 01
- Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Start of enrollment: 2014 Feb 01
Publications & Presentations
PubMed
- 9 citationsA Comprehensive Narrative Review on the History, Current Landscape, and Future Directions of Hepatocellular Carcinoma (HCC) Systemic Therapy.Alexander Lazzaro, Kevan L Hartshorn
Cancers. 2023-04-27 - 1 citationsReporting a Case of Solid Pseudopapillary Neoplasm of the Pancreas in a 44-Year-Old Woman with Parallel Analysis of Literature.Sargun Singh, Qing Zhao, Teviah E Sachs, Kevan Hartshorn
Case Reports in Oncological Medicine. 2023-01-01 - 8 citationsAberrant Cellular Glycosylation May Increase the Ability of Influenza Viruses to Escape Host Immune Responses through Modification of the Viral Glycome.Irina V Alymova, John F Cipollo, Lisa M Parsons, Nedzad Music, Ram P Kamal
Mbio. 2022-04-26
Journal Articles
- Innate Immunity and Influenza A Virus Pathogenesis: Lessons for COVID-19Kevan Hartshorn, MD, Frontiers in Cellular and Infection Microbiology
Press Mentions
Key Protein May Directly Impact Development of Colon CancerSeptember 21st, 2016
Grant Support
- Enhancing Collectin Mediated Defense Against InfluenzaNational Heart, Lung, And Blood Institute2011
- Collectin-Mediated Defense Against InfluenzaNational Heart, Lung, And Blood Institute2006–2010
- Enhancing Collectin-Mediated Defense Against InfluenzaNational Heart, Lung, And Blood Institute2002–2005
- Enhancing Collectin Mediated Host DefenseNational Heart, Lung, And Blood Institute1998–2001
- Neutrophil Activation By Viruses And Mammalian LectinsNational Institute Of Allergy And Infectious Diseases1995–1997
- Novel Viral Probe Of Neutrophil ActivationNational Institute Of Allergy And Infectious Diseases1990–1994
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
